Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01411124 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects
A Phase 1 study, sponsored by XenoPort.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01411124 is a Phase 1 study that has completed, run by XenoPort. The registered enrollment target is 36 participants.
The verdict
NCT01411124, a Phase 1 study, has completed, sponsored by XenoPort.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a double-blind, placebo-and active-controlled 3-period crossover study designed to assess the effect of GEn 600 mg on simulated driving performance in healthy volunteers.
Interventions
- DRUG placebo
- DRUG diphenhydramine
- DRUG gabapentin enacarbil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2011-06 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01411124
The ClinicalTrials.gov registry entry for NCT01411124 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is XenoPort, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01411124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01411124 about?
NCT01411124 is a clinical study titled "Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects". This is a double-blind, placebo-and active-controlled 3-period crossover study designed to assess the effect of GEn 600 mg on simulated driving performance in healthy volunteers.
What is the current status of trial NCT01411124?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2011-06. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01411124?
The interventions under investigation include: placebo (DRUG), diphenhydramine (DRUG), gabapentin enacarbil (DRUG).
Who is sponsoring clinical trial NCT01411124?
This trial is sponsored by XenoPort, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.